Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced that Provectus Chairman and CEO, Craig Dees, Ph.D. will present at the Big Dog IV Small Cap Conference being held at the Wynn Las Vegas on Friday, May 2^nd, 2008 at 10:40 a.m. PDT.

Dr. Dees said, “We are looking forward to telling attendees the Provectus story. As we continue to make significant strides in developing our oncological and dermatological therapies, we continue to strive to increase investor awareness and visibility of the Company. Utilizing the strategic communications program that our investor relations firm, Porter, LeVay & Rose has tailored for Provectus, we feel that the Big Dog Conference will provide yet another outlet for these purposes, and I am very proud to be presenting this week.�

Craig Dees, Ph.D., has spent more than 20 years in senior management positions at Photogen Technologies, Inc.; the Oak Ridge National Laboratory; LipoGen, Inc.; and TechAmerica, Inc. Dees was a founder, senior scientist and founding director of Photogen before Provectus was formed. His responsibilities have included product design and development in the fields of ethical vaccines, cosmetics, human diagnostics and over-the-counter pharmaceuticals. Dees holds a Ph.D. in molecular virology from University of Wisconsin, Madison. He earned his Master of Science degree in immunology from Auburn University, and his bachelor’s degree in microbiology from Brigham Young University.

About Big Dog IV Small Cap Conference

The Big Dog IV Small Cap Conference is scheduled to be held at the Wynn Las Vegas on May 1^st and 2^nd, 2008. Presenting companies will be making 20-25 minute presentations, followed by a 20 minute Q&A to a varied group of asset managers, hedge funds, brokers, analysts

and bankers. The Big Dog IV Small Cap Conference features companies across a broad selection of industry sectors. Senior executives will make group presentations to analysts and portfolio managers on their business strategy and outlook, and will be available for breakout sessions and one-on-one meetings.

About Provectus Pharmaceuticals, Inc. (www.pvct.com)

Provectus Pharmaceuticals is a development stage company that specializes in oncology and dermatology therapies that are safer, more effective, less invasive and more economical than conventional therapies. Provectus is currently conducting Phase 2 clinical trials of their proprietary drugs PV-10 as a therapy for metastatic melanoma and PH-10 as a topical treatment for moderate to severe psoriasis. Information about these and the Company’s other clinical trials can be found at the NIH registry, www.clinicaltrials.gov. The Company has received orphan drug designation from the FDA for its melanoma indication. Complementing their suite of proprietary drugs, Provectus has developed a number of intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For additional information about Provectus please visit the Company's website at www.pvct.com or contact Porter, LeVay & Rose, Inc. via the information provided above.

FORWARD-LOOKING STATEMENTS: The forward-looking statements contained herein are subject to certain risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management's analysis only as of the date hereof. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date thereof.

« Back to the Massage Creams Resource Center »